Cardiovascular disease (CVD) constitutes a real pandemic of the 21st century. According to
data from the Centers for Disease Control and Prevention, one person dies every 34 min …

Abstract Interleukin 1β (IL-1β) is a proinflammatory cytokine that has been implicated in a
number of rheumatologic and inflammatory conditions. The production and secretion of IL …

IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of
physiological functions traditionally associated with host defense, immune cell regulation …

Approximately 40% of heart attack survivors remain at increased risk of recurrent
cardiovascular events, despite the current treatment options showing that atherothrombosis …

Cardiovascular diseases are the leading cause of death worldwide. Research in the last two
decades has emphasized the inflammatory process as a key component in the …

IL-1β inhibition offers an interesting and biology-based opportunity to test the potential
beneficial effects of an anti-inflammatory therapeutic strategy in patients with CAD. A large …

Clinical trials have unequivocally shown that cholesterol-lowering drugs decrease the risk of
atherosclerotic cardiovascular disease in an exceptionally wide range of individuals. Yet …

Atherothrombosis is no longer considered solely a disorder of lipoprotein accumulation in
the arterial wall. Rather, the initiation and progression of atherosclerotic lesions is currently …

Interleukin‐1 blockade treatment decreasing cardiovascular risk - PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content …

It has recently been appreciated that atherosclerosis is predominantly an inflammatory
process. Atherosclerosis begins with a fatty streak, which is made up almost entirely of …